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Background
Despite many efforts to standardize drug skin tests only a
few position papers appeared. They were based mainly on
prick tests and to lesser extent on intradermal testing.
Their standardization is a task set by an ENDA group.
Our aim was to re-evaluate our drug skin tests (except
patch testing) performed during the past 30 years in a ret-
rospective study and to compare it with a newer protocol
applied since 2009.
Methods
In the first phase 185 “unselected” patients have been
tested upon suspicion of drug hypersensitivity causing
skin or general symptoms. Drug solutions of 1x10-3M
against solvent were injected into the volar surfaces of
forearms (403 tests). In 17 cases parallel tests with scari-
fication and 81 oral provocations with respective drugs
have been carried out as well. Tests were red at 20’;
70-90’ and 24 hrs. Drugs: Penicillin G, V; Ampicillin;
Aminopyrin; Sulfadimidin; Sulfametoxazol; Phenobarbi-
tal; Acetylsalicylic acid. The clinical phenotypes of the
hypersensitive event fell into 15 categories: including
MPE (26%), localized urticaria with/without ANO (19%),
generalized urticaria (19%) erythema multiforme, TEN
(4% each), Stevens Johnson’s and anaphylaxis (3.4%
each) and others. Positivity was accepted simply on the
two fold increase of the reaction against controls irre-
spective of its character: wheal or erythema. The
“improved” test (2009-) included additionally 5-10 µg/ml
histamine as positive control and restriction of positivity
only to wheal >5mm. Suspect patients (26) and 20 con-
trols were tested. The phenotypes due to previous
experience were MPE, Urticaria, ANO, AD, Anaphylaxis,
disseminated Erythemas.
Results
In the first phase out of 205 intradermal tests positivity has
occurred at 20’ in 62%, at 70-90’ in 52% and at 24 hrs.
in 33%. Scarification was all negative. 42% of oral provoca-
tions were positive. An indication for intradermal tests
based on the clinical phenotype was set up: MPE >45%
(body surface), Urticaria ±ANO (10-30%), Erythema multi-
forme, Bullous lesions of small extension, Anaphylaxis (gr.
I-II). All other phenotypes should not be tested. Compar-
ing “unselected” with “selected” group and testing various
drugs against provocation the overall intradermal positivity
went up from 43.2% to 77.5%. “Unselected” negativity was
94% against “selected” one of 80%. Histamine as positive
control has caused 103 mm wheal with 20-50 mm red
halo. Drugs with mol. mass <1000 Da were suitable for
standard test.
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